FREE e-zine for diagnostics pros. Subscribe now to this weekly email featuring G2's proprietary findings.
|
April 17-19, 2012 - Boston, MA
Features & Analysis
»2011 a Mixed Year for Diagnostics Industry
The year 2011 was a tumultuous one for the diagnostics industry. Some companies were able to thrive with record revenue growth and an increasingly promising pipeline, while others saw revenues plummet and stock prices tumble under the pressure of global economic uncertainties. more…
Copyright © 2012 Kennedy Information, LLC
June 6-8, 2012 - Las Vegas, NV
Features & Analysis
»FTC Approves LabCorp’s Acquisition of Orchid Cellmark But With Conditions
Following numerous extensions of its tender offer, LabCorp (Burlington, N.C.) in early December finally received approval from the Federal Trade Commission (FTC) to acquire Orchid Cellmark, but only under certain conditions. more…
Copyright © 2012 Kennedy Information, LLC
Events
Wednesday, March 7, 2012 2:00 p.m. - 3:30 p.m. EST
Features & Analysis
»Congress Defers Medicare Physician Pay Cut for Two Months; Last-Minute Deal Also Extends Pathology Grandfather Protection
In last-minute maneuverings, Congressional lawmakers Dec. 23 approved an amended version of payroll tax legislation that also would defer for two months a Medicare pay cut for physicians that had been due to be implemented Jan. 1. more…
Copyright © 2012 Kennedy Information, LLC
|
G2's FREE, weekly email gives you access to G2 market analysis, regulatory changes, M&A activity, leadership moves and more on the diagnostics industry. Recent articles include:
»Chromosomal Microarrays More Powerful than Karyotyping for Prenatal Testing
Stephanie Murg, Managing Director, G2 Intelligence Analyzing the DNA of a developing fetus through chromosomal microarray (CMA) provides more clinically relevant information than does standard karyotyping, a new study has found. Results of the multicenter, prospective, masked comparison of the two methods of prenatal testing were presented yesterday at the annual meeting of the Society for Maternal-Fetal Medicine in Dallas. more…
»Industry Executive Move: Life Technologies
Ronnie Andrews, former CEO of Clarient and segment leader for GE Molecular Diagnostics, has joined Life Technologies Corporation (Carlsbad, Calif.) as president, medical sciences. Andrews has more than 25 years of experience in the diagnostic industry, including leadership positions at companies such as Abbott Diagnostics and Roche Diagnostics. more…
»Palmetto Delays MolDx Implementation, Allows for Alternate Test Identifier
By Kimberly Scott, Managing Editor, G2 Intelligence
Palmetto GBA has changed the effective date for claim submissions under its new Molecular Diagnostic Services Program (MolDx) from March 1 to May 1 and will give laboratories a choice between applying for the McKesson Z-Code or an alternate test identifier from Palmetto. more…
More Insider
G2's FREE, daily email service brings you up-to-the-minute lab and diagnostics industry news from from across the spectrum of providers.
|
|
|